Engineers Gate Manager LP bought a new position in Taro Pharmaceutical Industries Ltd. (NYSE:TARO) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 2,211 shares of the company’s stock, valued at approximately $217,000.

Other hedge funds also recently added to or reduced their stakes in the company. Highstreet Asset Management Inc. lifted its holdings in shares of Taro Pharmaceutical Industries by 26.5% in the second quarter. Highstreet Asset Management Inc. now owns 5,355 shares of the company’s stock worth $620,000 after buying an additional 1,122 shares in the last quarter. Boston Partners purchased a new position in shares of Taro Pharmaceutical Industries in the second quarter worth $2,723,000. Schwab Charles Investment Management Inc. lifted its holdings in shares of Taro Pharmaceutical Industries by 25.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 10,026 shares of the company’s stock worth $1,160,000 after buying an additional 2,054 shares in the last quarter. Hikari Power Ltd purchased a new position in shares of Taro Pharmaceutical Industries in the second quarter worth $296,000. Finally, Alps Advisors Inc. lifted its holdings in shares of Taro Pharmaceutical Industries by 20.5% in the third quarter. Alps Advisors Inc. now owns 69,773 shares of the company’s stock worth $6,859,000 after buying an additional 11,849 shares in the last quarter. 10.68% of the stock is currently owned by hedge funds and other institutional investors.

TARO has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $120.00 target price on shares of Taro Pharmaceutical Industries in a report on Friday, August 10th. Zacks Investment Research downgraded shares of Taro Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Thursday, August 16th. Finally, ValuEngine downgraded shares of Taro Pharmaceutical Industries from a “hold” rating to a “sell” rating in a report on Monday, September 24th.

TARO stock opened at $99.86 on Monday. Taro Pharmaceutical Industries Ltd. has a one year low of $93.01 and a one year high of $121.23. The firm has a market capitalization of $3.94 billion, a PE ratio of 16.16 and a beta of 0.36.

Taro Pharmaceutical Industries (NYSE:TARO) last released its quarterly earnings results on Monday, November 5th. The company reported $1.60 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.96 by ($0.36). The business had revenue of $158.97 million for the quarter, compared to analysts’ expectations of $167.40 million. Taro Pharmaceutical Industries had a net margin of 36.33% and a return on equity of 11.99%. As a group, research analysts expect that Taro Pharmaceutical Industries Ltd. will post 7.65 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Engineers Gate Manager LP Buys New Holdings in Taro Pharmaceutical Industries Ltd. (TARO)” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2018/11/19/engineers-gate-manager-lp-buys-new-holdings-in-taro-pharmaceutical-industries-ltd-taro.html.

Taro Pharmaceutical Industries Profile

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.

Read More: Understanding each part of a balance sheet

Want to see what other hedge funds are holding TARO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taro Pharmaceutical Industries Ltd. (NYSE:TARO).

Institutional Ownership by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.